The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia.
 
Iman Aboudalle
No Relationships to Disclose
 
Ronald Paranal
No Relationships to Disclose
 
Shilpa Paul
No Relationships to Disclose
 
Wen Li
No Relationships to Disclose
 
Jing Ning
No Relationships to Disclose
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Immunogen (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Trovagene (Inst)
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Pfizer; Takeda
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; ARIAD; Bristol-Myers Squibb; Immunogen; Orsenix; Pfizer
Research Funding - Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
 
Ghayas C. Issa
No Relationships to Disclose